tradingkey.logo
tradingkey.logo
Search

Klotho Neurosciences Ord Shs

GRML
Add to Watchlist
3.570USD
-0.340-8.70%
Close 11-05 16:00(ET)
42.95MMarket Cap
LossP/E TTM
After-hours 18:18 (ET)3.510USD-0.075-2.09%

About Klotho Neurosciences Ord Shs Company

Klotho Neurosciences, Inc. operates with two divisions: Natural Resources and Cell and Gene Therapy. The Natural Resources division is focused on the exploration and development of the Skaergaard Project in Southeast Greenland, which is undeveloped palladium, gold, and platinum deposits. The Skaergaard Project is located in Southeast Greenland, which is an undeveloped palladium, gold, and platinum deposit. It operates three Mineral Exploration Licenses (MEL): MEL 2007-01, MEL 2012-25, and MEL 2021-10. The Cell and Gene Therapy division includes the Company's KLTO-202 primary indication for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s Disease). It is engaged in developing and providing new therapies to alleviate and/or reverse the progression of neurodegenerative diseases through the use of cell and gene therapy. It is also focusing on developing therapeutic agents for the treatments for Alzheimer's and Parkinson's disease.

Klotho Neurosciences Ord Shs Profile

Ticker Symbol- -
Company name- -
IPO date- -
CEO- -
Number of employees- -
Security type- -
Fiscal year-end- -
Address- -
City- -
Stock exchange- -
Country- -
Postal code- -
Phone- -
Website- -
Ticker Symbol- -
IPO date- -
CEO- -

Company Executives of Klotho Neurosciences Ord Shs

Name
Name/Position
Position
Shareholding
Change
Dr. Joseph Sinkule
Dr. Joseph Sinkule
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
126.93K
--
Dr. Joseph Sinkule
Dr. Joseph Sinkule
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
126.93K
--
Dr. Joseph Sinkule
Dr. Joseph Sinkule
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
126.93K
--
Dr. Samuel M. Zentman, Ph.D.
Dr. Samuel M. Zentman, Ph.D.
Independent Director
Independent Director
21.73K
--
Dr. Samuel M. Zentman, Ph.D.
Dr. Samuel M. Zentman, Ph.D.
Independent Director
Independent Director
21.73K
--
Dr. Samuel M. Zentman, Ph.D.
Dr. Samuel M. Zentman, Ph.D.
Independent Director
Independent Director
21.73K
--
Mr. Peter J. Moriarty
Mr. Peter J. Moriarty
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Jeffrey (Jeff) LeBlanc
Mr. Jeffrey (Jeff) LeBlanc
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jason D. Sawyer
Mr. Jason D. Sawyer
Director
Director
--
--
Mr. Jason Hawkins
Mr. Jason Hawkins
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Joseph Sinkule
Dr. Joseph Sinkule
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
126.93K
--
Dr. Joseph Sinkule
Dr. Joseph Sinkule
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
126.93K
--
Dr. Joseph Sinkule
Dr. Joseph Sinkule
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
126.93K
--
Dr. Samuel M. Zentman, Ph.D.
Dr. Samuel M. Zentman, Ph.D.
Independent Director
Independent Director
21.73K
--
Dr. Samuel M. Zentman, Ph.D.
Dr. Samuel M. Zentman, Ph.D.
Independent Director
Independent Director
21.73K
--
Dr. Samuel M. Zentman, Ph.D.
Dr. Samuel M. Zentman, Ph.D.
Independent Director
Independent Director
21.73K
--

FAQs

Who are the top five shareholders of Klotho Neurosciences Ord Shs?

The top five shareholders of Klotho Neurosciences Ord Shs are: Dr. Joseph Sinkule
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.